Changing Paradigms in Contrast Nephropathy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. A risk prediction model for contrast-induced nephropathy associated with gadolinium-based contrast agents.Renal failure · 2022
   Trial
2. Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy.International urology and nephrology · 2017
   Trial
3. Does intravenous contrast medium administration result in altered renal biomarkers? A study in clinically stable cats with and without azotemia.Journal of feline medicine and surgery · 2022
   Article
4. Minimal change disease and subacute interstitial nephritis in association withIDCases · 2021
   Article
5. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches.Journal of translational medicine · 2020
   Review

Corrections and comments

• Comment on
  Estimating the Risk of Radiocontrast-Associated Nephropathy.2017

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as